TheraRadar
← Back
Data updated: Jun 28, 2026

LAURUS GENERICS INC

Pharma

LAURUS GENERICS INC is a pharmaceutical company focused on Infectious Disease.

-
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

LAURUS GENERICS INC's Key Drugs

LAURUS GENERICS INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

LAURUS GENERICS INC's Recent FDA Approvals

New NDA/BLA approvals for LAURUS GENERICS INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LAURUS GENERICS INC's Therapeutic Areas

LAURUS GENERICS INC's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 100%
1 drugs

LAURUS GENERICS INC's Top Competitors

LAURUS GENERICS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

LAURUS GENERICS INC Pipeline Snapshot

Active clinical trials for LAURUS GENERICS INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling